Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Patients will receive injections of ranibizumab. In addition, patients will receive either Squalamine lactate 0.2% eye drops or Placebo eye drops. The study duration is approximately 9 months to primary endpoint
Epistemonikos ID: 4658c5c71eec3c53e80905d34631010d21fa4efb
First added on: May 12, 2024